No abstract

No abstract

Results: 41 RE patients met the inclusion criteria. 55%(n¼23) were male with a mean age of 64 (range, 44-90). Patients received 1-3 lines of chemotherapy before RE. There was no difference in tumor markers, or primary site location (right vs. left) between the two groups. 24 patients (58%) were classified as high tumor burden and 42%(n¼17) as low tumor volume. Median PFS in the high group was 3 months (95% CI 1.8-12.9) and in low group was 6 months (95% CI 5.5-14.4). Objective response in low tumor burden group was CR (n¼10), PR (n¼7), SD (n¼4) and PD (n¼3) vs. in high tumor burden group CR (n¼0), PR (n¼4), SD (n¼6), and PD(n¼7). Stratification of objective response to Y90 by tumor burden demonstrated statistically significant difference between high and low with low tumor burden resulting in improved response (P¼0.007). Correlation between tumor burden and PFS demonstrated a significant difference (P< 0.039). Conclusions: Tumor burden can be used as an independent predictor of response and progression-free survival to Y90 of hepatic mCRC.

No abstract